MedTrace Logo

SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

NCT02924714 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-02-18

No results posted yet for this study

Summary

The trial "The stop-GIST trial" is an Oslo University Hospital sponsored, prospective, open-label, 1-group, multicenter phase II trial evaluating discontinuation of imatinib in highly selected patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no detectable overt GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or radiofrequency ablation (RFA) of the metastases.

Conditions

  • Gastrointestinal Stromal Tumor

Interventions

OTHER

Discontinuation of imatinib

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Heikki Joensuu, MD PhD · Comprehensive Cancer Center Helsinki

  • Øyvind S Bruland, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02924714 on ClinicalTrials.gov